EGFR and cancer: Overexpression of these three genes was most significantly associated with panitumumab non-response aside from ERBB2, and thus may represent a relevant molecular pattern of panitumumab resistance by aberration and/or bypass of the EGFR signaling pathway for cancer cell survival.